Senores Pharmaceuticals Ltd

- Recently, promoters did a small pledge of shares mainly to consolidate some borrowings; no plans for increased pledging. - IPO proceeds include around INR100 crores earmarked for the Atlanta facility, which cannot be utilized for other purposes. - After the Apnar acquisition, cash reserves reduced, leaving about INR25 crores as of December 31, 2025. - Management anticipates needing an additional infusion of INR75 crores to INR100 crores over the next 12 months, primarily for new product acquisitions (ANDAs) and working capital. - To raise this amount, promoters have opted for a warrant structure allowing 25% contribution upfront, with the balance contributed over 6-12 months as needed. - The company did not find it efficient to tap the market for a small amount, hence the warrant-based fundraising. No mention of large-scale debt or equity fundraising currently planned beyond this.

- Capex for the next 2-3 years is expected to be around INR 50 crores to INR 100 crores, depending on the requirement. (Page 16) - Earlier planned capex in the US is now partly substituted due to the acquisition of Apnar Pharmaceuticals, providing extended capacity. (Page 15-16) - Expansion of the Atlanta Oral Solid Facility from 1 billion to 2 billion tablets is targeted to be completed by next year. (Page 15) - Apnar acquisition adds manufacturing capacity in India, enabling shift of some low-margin products from the US to India, optimizing facility utilization and margin profiles. (Page 15) - Around INR 100 crores from IPO proceeds is earmarked specifically for the Atlanta facility and cannot be used elsewhere. (Page 13) - An additional funding infusion of INR 75-100 crores over the next 12 months may be needed for new product acquisitions and working capital, managed partly through promoter warrants. (Page 13)

- Senores Pharmaceuticals targets robust growth in FY’27 and beyond, building on 50% growth guidance for FY’26. - The company expects to leverage Apnar acquisition and product launches (28 approved, 22 in development) to drive growth over the next 6-8 quarters. - Regulated market revenue mix is expected to shift towards 65% own products by FY’27, improving realizations and margins. - Emerging market business to continue growing with 56 product commercializations underway, driving revenue from distributor-led and export models. - Branded generics in India forecasted to grow significantly, with projected revenues of INR40-50 crores in FY’26 and INR80+ crores next year. - Overall, a 25%+ topline growth target is indicated, with potential for better bottom line growth, though 100% PAT growth is deemed unlikely. - Capacity expansions in India and US (including transfer of low-margin products to India) will support volume and margin improvements.

- The company has recorded 100% PAT growth for two consecutive years but considers repeating this level in FY’27 as "a little asking too much" due to the higher base (INR650+ crores PAT expected this year). - Targets a very decent top-line growth and slightly better bottom-line growth in FY’27. - EBITDA margins in the US regulated market expected to sustainably remain around 40%, with possible 1% improvement as more own products get commercialized. - Emerging markets EBITDA margins anticipated to improve to 18-22% in FY’27 and continue gaining modestly thereafter. - Apnar acquisition expected to contribute INR120-150 crores revenue in FY’27, with margin expansion as utilization improves. - Focus on cautious growth visibility quarter-over-quarter with multiple levers: product launches, capacity expansion, and transitioning production from US to India. - Management refrains from giving concrete 100% growth guidance for FY’27 but optimistic about strong growth momentum and margin improvement.

- The transcript on page 17 does not explicitly mention the current or expected order book or pending orders in numeric terms. - Swapnil Shah mentions that the company will keep updating the investor community on development sets and orders regularly. - The company is closely monitoring facility utilization and transitions of products from the US to India to optimize margins and capacity. - They have a strong product pipeline with 28 approved ANDAs yet to be launched over the next 6 to 8 quarters and 22 under development. - The acquisition of Apnar has added manufacturing capacity and product portfolios, expanding the order book potential. - Commercialization of 56 recently approved products in emerging markets is underway and expected to contribute substantially. - Overall, there is a positive outlook on orders linked to product launches, acquisitions, and market expansion, but exact order book numbers are not disclosed.